Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1678664

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1678664

Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Factor Deficiency Type, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Rare Hemophilia Factors Market Growth & Trends:

The global rare hemophilia factors market size is expected to reach USD 490.4 million by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factor concentrates gaining marketing approvals from regulatory bodies, such as the U.S. FDA, are expected to provide a significant push to the market growth. In addition, the rising adoption of prophylaxis treatment by patients is expected to boost market growth in the coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life. The COVID-19 pandemic had a significant impact on the market growth.

The pandemic's emphasis on patient safety and infection control measures led to an increased awareness and importance placed on safety measures in the administration of specific clotting factor therapies. Healthcare providers and patients became more conscientious about following hygienic practices during treatment administration, such as proper disinfection, hand hygiene, and the use of personal protective equipment. This increased emphasis on patient safety measures may have long-term benefits for the administration of rare hemophilia factors. Despite the challenges posed by the pandemic, there was still a high demand for specific clotting factor therapies for rare hemophilia. Patients with rare hemophilia types still required these therapies to effectively manage and treat their condition.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are boosting market growth. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs, and 554 drugs were approved by the U.S. FDA. The market players are constantly undertaking initiatives, such as innovative product launches and collaborations, to gain an advantage in the highly competitive market. For instance, in November 2022, the FDA announced its approval of an innovative gene therapy for the treatment of genetic blood-clotting Hemophilia B disorder. Kymriah, the gene-based therapy, is used for the treatment of B-cell precursor hemophilia patients below 25 years of age.

Rare Hemophilia Factors Market Report Highlights:

  • Factor VII deficiency dominated the market and accounted for a share of 35.1% in 2024. Factor XIII deficiency is expected to grow at the fastest CAGR of 7.1% over the forecast period.
  • Recombinant therapies led the market and accounted for a share of 50.3% in 2024. Prophylactic treatments are expected to register the fastest CAGR of 7.5% over the forecast period.
  • Hospital pharmacies held the largest market share of 59.9% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 9.2% over the forecast period.
  • North America rare hemophilia factors market dominated the global market with a revenue share of 38.7% in 2024. Asia Pacific rare hemophilia factors market is expected to register the fastest CAGR of 6.1% in the forecast period.
Show more
Product Code: GVR-2-68038-104-7

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Factor Deficiency Type
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rare Hemophilia Factors Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Rare Hemophilia Factors Market: Factor Deficiency Type Business Analysis

  • 4.1. Factor Deficiency Type Market Share, 2024 & 2030
  • 4.2. Factor Deficiency Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Factor Deficiency Type, 2018 to 2030 (USD Million)
  • 4.4. Factor VII Deficiency
    • 4.4.1. Factor VII Deficiency Market, 2018 - 2030 (USD Million)
  • 4.5. Factor XI Deficiency (Hemophilia C)
    • 4.5.1. Factor XI Deficiency (Hemophilia C) Market, 2018 - 2030 (USD Million)
  • 4.6. Factor XIII Deficiency
    • 4.6.1. Factor XIII Deficiency Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Rare Hemophilia Factors Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Recombinant Therapies
    • 5.4.1. Recombinant Therapies Market, 2018 - 2030 (USD Million)
  • 5.5. Plasma-derived Therapies
    • 5.5.1. Plasma-derived Therapies Market, 2018 - 2030 (USD Million)
  • 5.6. Prophylactic Treatments
    • 5.6.1. Prophylactic Treatments Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Rare Hemophilia Factors Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
  • 6.7. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Rare Hemophilia Factors Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Rare Hemophilia Factors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Rare Hemophilia Factors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Takeda Pharmaceutical Company Limited
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Biogen
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novo Nordisk A/S
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bayer AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. CSL
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Sanofi
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Swedish Orphan Biovitrum AB (publ)
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Octapharma AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Grifols, S.A.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. BioMarin
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
Show more
Product Code: GVR-2-68038-104-7

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 5. Global rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 6. Global rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 9. North America rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 10. North America rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 12. U.S. rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 13. U.S. Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 15. Canada rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 16. Canada rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 18. Mexico rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 19. Mexico rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 22. Europe rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 23. Europe rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 25. UK rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 26. UK Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 28. Germany rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 29. Germany rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 31. France rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 32. France Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 34. Italy rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 35. Italy rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 37. Spain rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 38. Spain rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 40. Norway rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 41. Norway Rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 43. Denmark rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 44. Denmark rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 46. Sweden rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 47. Sweden rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 53. Japan rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 54. Japan rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 56. China rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 57. China rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 59. India rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 60. India rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 62. Australia rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 63. Australia rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 65. South Korea rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 66. South Korea rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 68. Thailand rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 69. Thailand rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 72. Latin America rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 73. Latin America rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 75. Brazil rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 76. Brazil rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 78. Argentina rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 79. Argentina rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Rare hemophilia factors market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 85. South Africa rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 86. South Africa rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 91. UAE rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 92. UAE rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait rare hemophilia factors market, by factor deficiency type, 2018 - 2030 (USD Million)
  • Table 94. Kuwait rare hemophilia factors market, by drug class, 2018 - 2030 (USD Million)
  • Table 95. Kuwait rare hemophilia factors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Rare hemophilia factors market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Factor deficiency type and drug class outlook (USD Million)
  • Fig. 10 Distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Rare hemophilia factors market dynamics
  • Fig. 13 Rare hemophilia factors market: Porter's five forces analysis
  • Fig. 14 Rare hemophilia factors market: PESTLE analysis
  • Fig. 15 Rare hemophilia factors market: Factor deficiency type segment dashboard
  • Fig. 16 Rare hemophilia factors market: Factor deficiency type market share analysis, 2024 & 2030
  • Fig. 17 Factor VII deficiency market, 2018 - 2030 (USD Million)
  • Fig. 18 Factor XI deficiency (Hemophilia C) market, 2018 - 2030 (USD Million)
  • Fig. 19 Factor XIII deficiency market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Rare hemophilia factors market: Drug class segment dashboard
  • Fig. 22 Rare hemophilia factors market: Drug class market share analysis, 2024 & 2030
  • Fig. 23 Recombinant therapies market, 2018 - 2030 (USD Million)
  • Fig. 24 Plasma-derived therapies market, 2018 - 2030 (USD Million)
  • Fig. 25 Prophylactic treatments market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 Rare hemophilia factors market: Distribution channel segment dashboard
  • Fig. 28 Rare hemophilia factors market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 29 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 31 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 32 Rare hemophilia factors market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark country dynamics
  • Fig. 58 Denmark rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 62 China country dynamics
  • Fig. 63 China rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 64 India country dynamics
  • Fig. 65 India rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 66 Australia country dynamics
  • Fig. 67 Australia rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 68 South Korea country dynamics
  • Fig. 69 South Korea rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 72 Latin America rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 77 MEA rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait rare hemophilia factors market, 2018 - 2030 (USD Million)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!